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doi:10.1016/j.ejvs.2009.09.014Abstract Objectives: Acute mesenteric venous thrombosis (AMVT) was first reported by
Fagge and was recognised as a distinct clinical entity by Warreen in 1935. However, its
pathogenesis is still unclear. Elevated plasma levels of homocysteine (Hcy) are associated with
an increased risk of deep vein thrombosis. This case-control study examines the potential
association among hyperhomocysteinaemia (hyper-Hcy), low serum folate and vitamin B12
levels and the common C677T mutation of the MTHFR gene in patients with AMVT.
Materials and methods: Sixty-three patients with AMVT and 75 sex- and age-matched healthy
controls were recruited, and their plasma Hcy, folate and vitamin B12 levels were measured by
high performance liquid chromatography (HPLC) and immunological assays. The polymorphism
of MTHFR C677T was detected by PCR-RFLP.
Results: The mean plasma Hcy levels were significantly higher in patients with AVMT compared
with controls (23.5 standard deviation (S.D.) 8.8 vs. 12.6 6.6 mmol le1, P< 0.01). The fasting
Hcy correlated negatively with folate (AMVT: rZ e0.42, P < 0.01; Control: rZ e0.40,
P< 0.01). The frequency of homozygous (TT) genotype in MTHFR C677T mutation was signifi-
cantly higher in patients with AMVT than that in control subjects (33% vs. 17%; chi square
(c2)Z 6.31, P < 0.05; odds ratio (OR)Z 2.80; 95% confidence interval (CI): 1.25e6.25).
Compared with the control subjects, the mean serum vitamin B12 levels were lower in patients,
but it was not statistically significant (365 88 pmol le1 vs. 408 108 pmol le1, P> 0.05).Hu, Department of Vascular and Thyroid Surgery, First Affiliated Hospital, China Medical University,
(X.H. Hu).
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AMVT (nZ 63) 49.3 16.8 0
Control (nZ 128) 43.2 13.2 0
P Value n.s. nConclusions: Hyper-Hcy and low serum folate levels were associated with an increased risk of
AMVT. The homozygous (TT) genotype of MTHFR gene mutation may be a crucial hereditary risk
factor in the development of AMVT for a Chinese population.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Acute mesenteric venous thrombosis (AMVT) is an
uncommon form of intestinal ischaemia with high mortality,
comprising 5e15% of all cases with acute mesenteric
ischaemia.1e3 The prompt diagnosis of AMVT is usually
missed because of its non-specific abdominal syndrome,
and this disease is often identified at laparotomy or
autopsy. The high mortality can be attributed to misdiag-
nosis rate (90e95%) and increasing postoperative compli-
cations. However, increased awareness of the causes of
AMVT and improvements in imaging techniques have
facilitated recognition of this disease, leaving more time
for non-operative management. Our retrospective study
suggested that non-operative management had a lower
mortality rate and shorter hospital stay than that of
operative management, although both survival rates were
similar.4 However, its pathogenesis is still unclear. Hyper-
homocysteinaemia (hyper-Hcy) was well known to be a risk
factor for thrombo-embolism. Genetic factors are impor-
tant determinants of homocysteine (Hcy) metabolism,
because the mutant of methylene tetrahydrofolate reduc-
tase (MTHFR) C677T causes moderate hyper-Hcy, which is
due to a defective function of the enzyme.5 In addition,
folate and vitamin B12 as coenzymes could take part in
redox and metabolic reactions of Hcy.6 To prevent the
occurrence and recurrence of AMVT, we made this further
study to evaluate the roles of plasma Hcy, folate and
vitamin B12 levels and the C677T mutation in MTHFR gene in
the development of AMVT.Materials and Methods
Cases
From January 2002 to December 2007, a total of 63 patients
(49 men, 14 women; mean age, 49.3 16.8 years [range:
29e67 years]) with AMVT as group AMVTwere selected from
the First Affiliated Hospital and Shengjing Hospital of China
Medical University, and these patients all came from
Northeast China. Of the selected patients, 55 were
diagnosed with AMVT by enhanced computed tomography
(CT), of which 29 cases were further confirmed as AMVTtients with AMVT and control s
ther
hrombosis
r sclerosis
Smoking gender
male
18/63 49/63
23/128 95/128
.s. n.s. n.s.after surgery. The remaining eight of the selected cases
were confirmed as AMVT after laparotomy. The patients
(0 cases) receiving vitamin supplementation or substances,
affecting Hcy metabolism, within 6 months were excluded.
We also excluded the patients with other venous thrombo-
embolism (two cases with lower limb deep venous throm-
bosis) and clear hypercoagulability status, which was
caused by certain conditions such as cirrhotic portal
hypertension (eight cases), thrombocythemia (0 cases),
post-splenectomy syndrome (0 cases), nephritic syndrome
(0 cases), hypercythemia (three cases) and cancer
(0 cases). Prothrombin (Pt) test, activated partial throm-
boplastin time (APTT) test, fibrinogen (Fg) test and D-D/D-
dimer test were included in the coagulation screen. In all,
13 patients were excluded. Only survivors of AMVT were
recruited; no patients had died after hospital discharge by
the 3-month blood collection. After the follow-up of
1.5e4.5 years, two patients died from gastrointestinal
haemorrhage and cerebral haemorrhage, respectively.
There was no patient with known diseases that influenced
Hcy concentration, such as renal or thyroid disease. The
serum creatinine levels in the 63 patients were normal.
Control subjects
A total of 75 sex- and age-matched healthy individuals
(blood donors all from the Blood Donation Centres in
Liaoning province) from the same geographic areas were
included as the control group (56 men, 19 women; mean
age, 44.5 12.2 years [range: 22e60]) and were free of
overt disease according to a questionnaire. The criteria for
recruiting control subjects were lack of any history of
thrombo-embolic events and not taking any medicine in the
most recent 4 months. In this study, the entire population
was Chinese from Northeast China; furthermore, there is
non-kinship among these individuals (Table 1).
The study was approved by the local ethics committee
and informed consent was obtained from all study subjects.
Laboratory tests
Immunological assays were used to determine the serum
concentrations of folate and vitamin B12, while high
performance liquid chromatography (HPLC) was used toubjects.
hyper-Hcy Hcy mmol/L Folate
nmol/L
vitamin B12
pmol/Lfemale
14/63 58/63 (92%) 23.5 8.8 3.7 1.8 365 88
33/128 13/128 (10%) 12.6 6.6 7.6 2.6 408 108
n.s. P< 0.01 P< 0.01 P< 0.01 n.s.
Figure 1 PCR-RFLP of MTHFR gene polymorphism using HinF1
restriction endonuclease. Lane M: 100 bp DNA ladder Marker;
Lane 1, 3: CC genotype; Lane 2, 6: TT genotype; Lane 4, 5: CT
genotype.
510 J.A. He et al.determine plasma Hcy levels. Hyper-Hcy was defined by
fasting Hcy exceeding 95th percentile of the gender-
specific distribution (men: 19.5 mmol le1; women:
15.0 mmol le1).7 Low folate levels were defined by fasting
folate falling below 10th percentile (5.11 nmol le1).
For molecular genetics analysis, DNA was extracted from
a fraction of a peripheral blood sample using the phenole
chlorophormeisoamylic alcohol method, and its amount
was determined by ultraviolet spectrophotometer. For
identification of the C677T mutation in the MTHFR gene,
polymerase chain reaction (PCR) was performed as follows.
Initial denaturation step was for 2 min at 94 C followed by
40 cycles of denaturation for 30 s at 94 C, annealing for
30 s at 62 C and elongation for 5 min at 72 C. Primers used
were primer A, 50TGAAGGAGAAGGTGTCTGCGGGA30 and
primer B, 50AGGACGGTGCGGTGAGAGTG30. PCR products
(10 ml) were used to mixed with 10 buffer solution (2 ml),
restriction endonuclease (HinF1 5 U) and deionised water
until final volume is up to 20 ml. This liquor was incubated
for 3 h at 37 C. Digested PCR products were visualised by
ethidium bromide staining (0.5 mg le1) of a 3% agarose gel.
Statistical methods
Analysis was conducted with SPSS version 10 for Windows
(SPSS Inc., Chicago, IL, USA). Distribution of genotype and
allele frequencies of MTHFR C677T in patients and controls
was determined, and odds ratio (OR) and its 95% confidence
interval (CI) were calculated. On the basis of the results
obtained, statistical differences existed in the above-
mentioned factors (hyper-Hcy, low serum folate levels and
MTHFR C677T mutation) between patients with AMVT and
control subjects were revealed by the Student’s t-test and
chi square (c2) analysis. The plasma Hcy, folate and vitamin
B12 levels and age were calculated as mean values (stan-
dard deviation (S.D.) and analysed using the Student’s
t-test. Statistical significance was set at P< 0.05 or
P< 0.01, respectively.
Results
No significant difference was observed in the mean age of
subjects in the case and control groups (Table 1). The
plasma Hcy levels were significantly higher in patients with
AMVT compared with that in control subjects (23.5 8.8 vs.
12.6 6.6 mmol le1, P< 0.01). By contrast, the mean serum
folate levels were significantly lower in patients with AMVT
compared with control subjects (3.7 1.8 vs.
7.6 2.6 mmol le1, P< 0.01). There is a negative correla-
tion between plasma Hcy and serum folate (group AMVT:
rZe0.42, P< 0.01; group control: rZe0.40, P< 0.01).
However, the mean serum vitamin B12 levels of the two
groups have shown no significant difference on statistics
(P> 0.05). Hyper-Hcy was diagnosed in 58 patients and 13
control subjects (92% vs. 10%, P< 0.01, Table 1).
The C677T substitution generates a HinF1 restriction
recognition sequence, and restriction digestion gives two
fragments of 175 and 23 bp. The 23-bp fragment was not
seen under our experimental conditions. Normal homozy-
gote (CC) was identified by the presence of a 198-bp frag-
ment, C677T homozygote (TT) by the presence of a 175-bpfragment and heterozygote (CT) by the presence of both
fragments. Digested PCR products were visualised by
ethidium bromide staining (0.5 mg le1) of a 3% agarose gel
(Fig. 1).
In patients with AMVT, the frequency of the homozygous
form (TT) in MTHFR C677T mutation was significantly higher
than that in control subjects (33% vs. 17%, P< 0.05;
ORZ 2.80; 95% CI: 1.25e6.25) and the frequency of the T
allele was significantly increased in patients compared with
normal controls (P< 0.05; ORZ 1.71; 95% CI: 1.12e2.63).
The study showed that there was a marked positive corre-
lation between TT genotype and development of AMVT
(Table 2). The chi square (c2) analysis demonstrated that
genotype frequencies in the two groups did not depart from
the HardyeWeinberg equilibrium.
In this study, genotypes and alleles of MTHFR C677T
mutation including genotypes CC, CT, TT, C allele and T
allele. In the AMVT group, the mean plasma Hcy levels of CT
or TT genotype carriers were all significantly higher than
those of CC genotype carriers (P< 0.05). However, in the
control group, only the mean plasma Hcy levels of TT
genotype carriers were significantly higher than those of CC
genotype carriers (P< 0.05). In general, the mean plasma
Hcy levels were significantly higher in the AMVT group
compared with the control group regardless of genotypes
(P< 0.05, Table 3).Discussions
Hyper-Hcy is well known to cause venous and arterial
thrombo-embolism.8e10 Epidemiological studies also have
suggested that even mild hyper-Hcy is associated with
occlusive arterial vascular disease and venous thrombo-
embolism.11e15 As a sulphur amino acid in the human body,
Hcy is an intermediate product in the metabolism of
methionine. It is suggested that high plasma levels of total
homocysteine (tHcy) result from the interaction between
genetic and acquired determinants.16 The thermolabile
mutant of MTHFR causes moderate hyper-Hcy, which is due
to a defective function of the enzyme. The main genetic
defect related to hyper-Hcy is a C to T substitution at
nucleotide 677 in the encoding region of the MTHFR gene,
converting the codon for alanine to valine.5 Several inves-
tigations have shown that the thermolabile mutant MTHFR
C677T causes an increased risk for thrombosis.17e20 A meta-
analysis done by den Heijer showed that the pooled OR for
Table 2 Prevalence of the MTHFR 677C/T genotype and allele in patients with AMVT and control subjects.
(AMVT group)
nZ 63(%)
(Control group)
nZ 128(%)
P value OR (95%CI)
Genotype
CC 15 (24) 26(35) c2Z 2.21 (P> 0.05) 1.0
CT 27 (43) 36(48) c2Z 0.53 (P> 0.05)
TT 21 (33) 13(17) c2Z 6.31(0.01< P< 0.05) 2.80 (1.25e6.25)
Allele
C 57(45) 88 (59)
T 69(55) 62 (41) c2Z 6.07(0.01< P< 0.05) 1.71 (1.12e2.63)
Acute Mesenteric Venous Thrombosis 511venous thrombosis was 2.5 (95% CI: 1.8e3.5) in patients
with fasting hyper-Hcy.8 This result and those from other
studies all suggested that hyper-Hcy was a risk factor for
venous thrombosis.21e23 Several in vitro studies suggested
that Hcy interfered with the anticoagulant and fibrinolytic
systems.24,25 It also had injurious effects on the endothelial
cells, inducing vascular damage,26 which was also sug-
gested by Gatt A and Makris M.27
Our study results showed that the mean plasma Hcy
levels of the patients with AMVT were significantly higher
than those of the controls, so we believe that there must be
an association between high plasma levels of Hcy and the
development of AMVT. In our study, we also deduced that
there was an association between plasma levels of Hcy and
homozygous (TT) genotype in MTHFR gene mutation. Based
on our observations, in the AMVT group, the mean plasma
Hcy levels of CT or TT genotype carriers were all signifi-
cantly higher than those of CC genotype carriers. However,
in the control group, only the mean plasma Hcy levels of TT
genotype carriers were significantly higher than those of CC
genotype carriers. This result demonstrated that the
development of hyper-Hcy was mainly due to the homozy-
gous C677TT mutation in the MTHFR gene, which might be
an important hereditary factor in patients with AMVT.
Furthermore, our study results also showed that the mean
plasma Hcy levels were significantly higher in the AMVT
group compared with the control group regardless of
genotypes, indicating that hyper-Hcy was an important risk
factor for AMVT. We can also deduce that the homozygous
C677TT mutation in the MTHFR gene plays an important
role in the development of AMVT by increasing the plasma
Hcy levels, and the homozygous C677TT genotype might be
an important hereditary risk factor. It showed that the
homozygous form in MTHFR C677T mutation was associated
with the development of thrombosis disease for a Chinese
population.28 However, with regard to AMVT, the impact of
homozygous form in MTHFR C677T mutation on it has not
been reported.Table 3 Comparison of plasma Hcy among different genotype c
Group n Hcy CC genotype
n Hcy
AMVT group 63 23.5 8.8# 15/63 16.9 6.
Control group 75 12.6 6.6 26/75 10.8 5.
*Compared with CC genotype carriers in the same group, P< 0.05.
#Compared with the control group, P< 0.05.Cattaneo demonstrated recently that vitamin defi-
ciencies are common in patients with deep vein throm-
bosis.6 When the association between vitamin state and the
risk of deep vein thrombosis was investigated, a statistically
significant association was found for low levels of vitamin B6
but not of vitamin B12. Our finding was consistent with this
result, but we do not measure the serum vitamin B6 levels
at the same time.
Our study also found that there was obvious negative
correlation between the plasma levels of Hcy and the
serum levels of folate, which suggested the deficiency of
folate was another important risk factor for hyper-Hcy,
because folate and vitamin B12 as coenzymes could take
part in redox and metabolic reactions of Hcy. Thus,
hyper-Hcy is not only associated with the MTHFR C677T
mutation, but also with trophic levels especially including
the serum levels of folate. Nagaraja also proved that
there was a significant inverse correlation between folate
and tHcy levels in patients with puerperal cerebral
venous thrombosis (CVT), regular antenatal folate and
vitamin B12 supplementation is likely to lower puerperal
tHcy levels.29 Acosta suggested that lifelong anti-
coagulation should be considered in patients with AMVT.30
However, severe haemorrhagic complications of antico-
agulant treatment also should be considered. Thus, we
suggest that the correction of hyper-Hcy with folate
therapy will perhaps help to prevent the occurrence of
AMVT. Some other studies showed that vitamin therapy
will help to reduce the high risk of recurrent cerebral
vein thrombosis (up to 20%).31,32 A meta-analysis of the
short-term trials of therapy with folate showed a reduc-
tion of 25% of hyper-Hcy and a further reduction of 7%
when vitamin B12 was associated. This situation may be
associated with a 10e20% decreased risk of venous
thrombosis.33 Especially for the Chinese population from
Northeast China, AMVT often occurred because of cold
weather, deficiencies of fresh fruits and vegetables rich
in folate. Furthermore, bad dietary habits andarriers (x SD, mmol/L).
CT genotype TT genotype
n Hcy n Hcy
6# 27/63 24.0 7.2*# 21/63 28.6 9.5*#
6 37/75 12.6 5.4 12/75 18.8 6.2*
512 J.A. He et al.socioeconomic conditions can also increase the risk of
venous thrombosis.34 The aetiology of AMVT is compli-
cated. A multifactorial interaction may be responsible for
AMVT, so we should make further studies to find other
mechanisms and to improve levels of prevention, diag-
nosis, therapy and outcomes of AMVT.
Study limitations are inherent in a case-control design.
Although cases were classified prospectively and recruited
consecutively and controls were chosen from the same
source as cases, potential confounding can never be elimi-
nated. However, case-control studies are particularly useful
for assessing uncommon disorders such as AMVT, for which
case-control studies may be the only practical approach.
There were some missing variables in our control subjects
that could have influenced plasma Hcy levels. Renal function
is an important determinant of plasma Hcy levels. Serum
creatinine was not determined in our controls, as they were
selected from an apparently healthy population with low
probability of renal dysfunction. We also know that hyper-
hcy differs depending on age, so we chose the control
subjects according to the distributions of gender and age of
case group. We mainly paid our attention to the comparison
of two groups’ hcy levels. The upper range values used were
based on our hospital’s normal data.
In summary, the present case-control study suggested
that hyper-Hcy, low folate concentrations and homozygous
C677TT mutation in the MTHFR gene were the risk factors in
the development of AMVT. So folate therapy for patients
with hyper-Hcy or AMVT might have the potential to
prevent the occurrence of AMVT and to decrease the risk of
recurrence. A randomised control test should be carried out
to investigate the effects of folate therapy on AMVT in the
future.
Conflict of Interest
The authors have no conflicts of interest concerning
disclosure.Acknowledgements
Funding: This work was supported by Nature Science
Foundation of China (30672048, 30600361 and 30872527).
References
1 Warren S, Eberhardt TP. Mesenteric venous thrombosis. Surg
Gynecol Obstet 1935;61:102e20.
2 Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N
Engl J Med 2001;345:1683e8.
3 Eliot JW. The operative relief of gangrene of the intestine due
to occlusion of the mesenteric vessels. Ann Surg 1895;21:9e23.
4 ?A3B2 twb=0.25w?>Zhang J, Duan ZQ, Song QB, Luo YW, Xin SJ,
Zhang Q. Acute mesenteric venous thrombosis: a better
outcome achieved through improved imaging techniques and
a changed policy of clinical management. Eur J Vasc Endovasc
Surg 2004;28:329e34.
5 Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA,
Matthews RG, et al. A candidate genetic risk factor for vascular
disease: a common mutation in methylenetetrahydrofolate
reductase. Nat Genet 1995;10:111e3.6 Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P, Mannucci PM.
Low plasma levels of vitamin B6 are independently associated
with a heightened risk of deep-vein thrombosis. Circulation
2001;104:2442e6.
7 Fermo I, Vigano S, Paroni R, Mazzola G, Calori G, D’Angelo A.
Prevalence of moderate hyperhomocysteinemia in patients with
early onset venous and arterial thrombosis. Ann Intern Med
1995;123:747e53.
8 den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM.
Hyperhomocysteinemia and venous thrombosis: a meta-anal-
ysis. Thromb Haemost 1998;80:874e7.
9 Wuillemin WA, Solenthaler M. Hyperhomocysteinemia: a risk
factor for arterial and venous thrombosis. Vasa 1999;28:151e5.
10 den Heljer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH,
et al. Hyperhomocysteinemia as a risk factor for deep-vein
thrombosis. N Engl J Med 1996;334:759e62.
11 Homocysteine Studies Collaboration. Homocysteine and risk of
ischemic heart disease and stroke. A meta-analysis. JAMA 2002;
288:2015e22.
12 Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM.
High prevalence of hyperhomocyst(e)inemia in patients with
juvenile venous thrombosis. Arterioscler Thromb Vasc Biol
1994;14:1080e3.
13 den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL. Is
hyperhomocysteinaemia a risk factor for recurrent venous
thrombosis? Lancet 1995;345:882e5.
14 Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C,
Ferrari V, et al. Hyperhomocysteinemia and deep-vein throm-
bosis: a case control study. Thromb Haemost 1996;76:883e6.
15 Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor
for venous thromboembolic disease. Arch Intern Med 1998;158:
2101e6.
16 Cattaneo M. Hyperhomocysteinemia, atherosclerosis and
thrombosis. Thromb Haemost 1999;81:165e76.
17 Kang SS, Wong PW, Zhou JM, Sora J, Lessick M, Ruggie N,
et al. Thermolabile methylenetetrahydrofolate reductase in
patients with coronary artery disease. Metabol 1988;37:
611e3.
18 Cattaneo M, Tsai MY, Bucciarelli P, Taioli E, Zighetti ML. Bignell
reductase gene (C677T) increases the risk for deep-vein
thrombosis in patients with mutant factor V (factor V: Q506).
Arterioscler Thromb Vasc Biol 1997;17:1662e6.
19 Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P,
Stevens EM, van Oost BA, et al. Molecular genetic analysis in
mild hyperhomocysteinemia: a common mutation in the
methylenetetrahydrofolate reductase gene is a genetic risk
factor for cardiovascular disease. Am J Hum Genet 1996;58:
35e41.
20 Arruda VR, von Zuben PM, Chiaparini LC, Annichino-
Bizzacchi JM, Costa FF. The mutation Ala677 / Val in the
methylene tetrahydrofolate reductase gene: a risk factor for
arterial disease and venous thrombosis. Thromb Haemost 1997;
77:818e21.
21 Hsu T, Hsu L, Chang C, Sun C, Ko Y, Kuo C, et al. Importance of
hyperhomocysteinemia as a risk factor for venous thromboem-
bolism in a Taiwanese population. A caseecontrol study.
Thromb Res 2001;102:387e95.
22 Weger M, Stanger O, Haas A. Hyperhomocysteinemia: a risk
factor for central retinal vein occlusion. Am J Ophthalmol 2001;
131:290e1.
23 Langman LJ, Ray JG, Evrovski J, Yeo E, Cole DE. Hyper-
homocyst(e) inemia and the increased risk of venous thrombo-
embolism: more evidence from a caseecontrol study. Arch
Intern Med 2000;160:961e4.
24 Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers G-M.
Homocysteine, a risk factor for premature vascular disease and
thrombosis, induces tissue factor activity in endothelial cells.
Arterioscler Thromb 1993;13:1327e33.
Acute Mesenteric Venous Thrombosis 51325 Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus,
reduces protein C activation by arterial and venous endothelial
cells. Blood 1990;75:895e901.
26 Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis:
pathogenic mechanisms predisposing to thrombosis. J Nutr
1996;126(Suppl. 4):1285Se9S.
27 Gatt A, Markris M. Hyperhomocysteinemia and venous throm-
bosis. Semin Hematol 2007;44:70e6.
28 Ho CH, Kuo BI, Kong CW, Chau WK, Hsu HC, Gau JP, et al.
Influence of methylenetetrahydrofolate reductase (MTHFR)
C677T polymorphism, B vitamins and other factors on plasma
homocysteine and risk of thromboembolic disease in Chinese.
J Chin Med Assoc 2005;68:560e5.
29 Nagaraja D, Noone ML, Bharatkumar VP, Christopher RJ.
Homocysteine, folate and vitamin B12 in puerperal cerebral
venous thrombosis. Neurol Sci 2008;272:43e7.30 Acosta S, Alhadad A, Svensson P, Ekberg O. Epidemiology, risk
and prognostic factors in mesenteric venous thrombosis. Br
J Surg 2008;95:1245e51.
31 Preter M, Tzourio C, Ameri A, Bousser MG. Longterm prognosis
in cerebral venous thrombosis. Follow-up of 77 patients. Stroke
1996;27:243e6.
32 Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM.
Hyperhomocysteinemia in cerebral vein thrombosis. Blood
2003;102:1363e6.
33 Hotxoleanu C, Porojan-Iuga M, Rusu ML, Andercou A. Hyper-
homocysteinemia: clinical and therapeutical involvement in
venous thrombosis. Rom J Intern Med 2007;45:159e64.
34 Cantu C, Alonso E, Jara A, Martı´nez L, Rı´os C, Ferna´ndez Mde L,
et al. Hyperhomocysteinemia, low folate and vitamin B12
concentrations, and methylene tetrahydrofolate reductase
mutation in cerebral venous thrombosis. Stroke 2004;35:1790e4.
